Shares of Grace Therapeutics, Inc. (NASDAQ:GRCE – Get Free Report) were down 0.4% during mid-day trading on Thursday . The stock traded as low as $2.25 and last traded at $2.29. Approximately 27,548 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 91,147 shares. The stock had previously closed at $2.30.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Grace Therapeutics in a research note on Tuesday, February 18th.
Get Our Latest Stock Report on Grace Therapeutics
Grace Therapeutics Trading Down 4.8 %
Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. Equities research analysts anticipate that Grace Therapeutics, Inc. will post -1.06 earnings per share for the current year.
About Grace Therapeutics
Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.
Featured Articles
- Five stocks we like better than Grace Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Insider Trading – What You Need to Know
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
